The fight against the COVID-19 can be faced through the correct and responsible sharing of information!
Thanks to the availability of several information means, the spreading of fake news is increasing and it reaches everyone.
Sharing information, most of all in such a crucial situation, is an act of huge responsibility and awareness.
You can easily recognise a fake news by using some of the tips suggested by Fondazione Gianni Benzi.
Among them, consulting news and information from official and verified sources is very important. An example of reliable source is the Agenzia Italiana del Farmaco (AIFA) that is currently evaluating all the available scientific evidences in order to undertake actions (including also the fast track authorisation for clinical studies), based on strong scientific data, needed to promptly ensure the best therapeutic options for COVID-19.
In particular, considering the antiviral Favipiravir (trade name Avigan), AIFA confirmed that nowadays there are not clinical studies related to the efficacy and safety of this drug for the treatment of COVID-19.
Favipiravir is an antiviral authorised in Japan since March 2014 for the treatment of different flu forms caused by novel or known flu viruses. Its use is limited to the cases in which the other antivirals are not efficient. The medicine has not been authorised in Europe nor in the United States.
Currently only preliminary data from one small clinical study are available and they have not been revised by experts yet. The clinical study was conducted on patients with not serious COVID-19 occurred from 7 days. In this study the Favipiravir was compared to the antiviral Lopinavir/Ritonavir (not authorised as well), associated with Interferon alfa-1b via aerosol.
Even though it seems that the available data suggest a potential activity of Favipiravir, mainly for the virus disappearance time from the blood and for some radiologic parameters, data on the real efficacy on the clinical use and the disease evolution are missing.
Therefore, the AIFA scientific board, gathered on the 23rd March, evaluated the preliminary and limited evidences of the drug activity and it is developing a program for clinical studies on the efficacy and safety of this treatment.
Spread the word and promote the sharing of correct information!